{"id":"NCT05372419","sponsor":"Eli Lilly and Company","briefTitle":"A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color","officialTitle":"An Open-Label, 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-01-12","primaryCompletion":"2024-05-03","completion":"2025-02-17","firstPosted":"2022-05-12","resultsPosted":"2025-06-11","lastUpdate":"2025-06-11"},"enrollment":90,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Lebrikizumab","otherNames":["LY3650150","DRM06"]}],"arms":[{"label":"Lebrikizumab 250 mg Q2W","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.","primaryOutcome":{"measure":"Percentage of Participants Achieving Eczema Area and Severity Index 75 (â‰¥75% Reduction From Baseline in EASI) at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Lebrikizumab 250 mg Q2W","deltaMin":69.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":11},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":["40665146"],"seeAlso":["https://trials.lilly.com/en-US/trial/343503"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":90},"commonTop":["Nasopharyngitis","Back pain","Tachycardia","Blepharitis","Dry eye"]}}